menu
    • menu

    Company profile for Sichuan Elixir Pharmaceuticals

    Sichuan Elixir-PSE
    News
    The August Suzhou meeting concluded successfully!

    26 Aug 2024

    // PRESS RELEASE

    Teva, Sanofi say bowel disease drug met primary targets

    18 Dec 2024

    // PRESS RELEASE

    FDA warns online vendors selling unapproved weight-loss drugs

    18 Dec 2024

    // REUTERS

    DATA COMPILATION
    #PharmaFlow

    Sichuan Elixir Pharmaceuticals

    Contact Supplier

    Website

    Antibody Engineering

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    Key Products KEY PRODUCTS

    PharmaCompass

    Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

    Related CompaniesRelated Companies

    About

    Specializing in natural & oncology APIs, we establish R&D and production platforms for new salt, crystal form & synthetic biology research. We cooperate with clients for IND, NDA, ANDA, 505b(2) and P-IV challenges. Exploring macromolecular APIs, we focus on Glycans & polypeptides. Expertise in XDC drugs drives innovative research & payload production. With a global registration platform & international cGMP system, we offer API CMO/CDMO services worldwide. Our strategy combines FDF and APIs. Our labs meet GMP standards with a stable R&D team, over 10 years of experience, we've delivered 20+ successful projects.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sichuan Elixir PharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    Room 2018/2019, Building M3, Huanhui Commercial Plaza, High-tech Zone, Chengdu...
    Telephone
    Telephone
    +86 2889101770, +86 2889106518
    Client Email
    Email
    sales@elixir-pharm.com
    Client Website
    Website
    http://www.elixir-pharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/sichuan-elixir-pharmaceuticals-party-content-28544.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/sichuan-elixir-pharmaceuticals-party-content-52838.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF submissions from China jump 42% as India continues to top list in Q1 2024

    DMF submissions from China jump 42% as India continues to top list in Q1 2024

    Generic drugs play a crucial role in providing access to life-saving drugs at affordable prices. To that end, drugmakers submit Drug Master Files (DMFs) or their ‘recipes for making generics’ to the US Food and Drug Administration (FDA) for review. Of these, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs.PharmaCompass has been reviewing Type II submissions for several years now. We have noticed that these filings have been increasing in recent years. There has been a 33.5 percent increase in Type II DMF submissions since Q1 2018 (when 176 Type II DMFs had been submitted). However, at 235, the first quarter (Q1) of 2024 saw only a 1.3 percent increase in DMF submissions over Q1 2023. In Q1 2023, DMF submissions had increased by 21.5 percent (over Q1 2022).Of the 235 Type II submissions received by the FDA in Q1 of this year, only 35 (or around 15 percent) had their review completed under the Generic Drug User Fee Act (GDUFA). The total number of reviews completed by the US federal agency so far this year is 129.In all, FDA received 353 Type II, III, IV, and V DMF submissions, compared to 291 in Q1 2023, an increase of 21.3 percent.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available)DMF submissions from India dip 1.8%; China witnesses 42% rise in filings As has been the trend, India (dubbed as the pharmacy of the world) and China filed the maximum DMF submissions, with 107 and 101 submissions respectively. However, DMFs filed by Indian companies saw a marginal dip of 1.8 percent in Q1 2024 — in Q1 2023, Indian companies had filed 109 Type II DMFs. Meanwhile, DMF filings by Chinese drugmakers increased 42.2 percent in Q1 2024, up from 71 in Q1 2023.India’s MSN Laboratories was the clear leader with 15 DMF submissions to the FDA, while China’s Sichuan Elixir Pharmaceutical came a distant second with nine submissions. Indian drugmakers Aurobindo Pharma and Global Calcium (with seven submissions each) were tied at third position. There were two players at the fifth spot — India’s Dr. Reddy’s Laboratories and China’s Zhejiang Jingsheng Pharmaceutical — as both these drugmakers registered six submissions each.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Diabetes, cancer drugs emerge as hot molecules in Q1 2024Approved in June 2020, triheptanoin is the first and only FDA-approved treatment for children and adults with long-chain fatty acid oxidation disorders (LC-FAOD). At five, triheptanoin saw the maximum DMF filings. Four of those applications have already been positively reviewed.Anti-diabetic drug sitagliptin phosphate monohydrate saw four DMF filings. Empagliflozin, the API found in Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, drew three DMF filings in Q1 2024.In the US, Jazz Pharmaceuticals’ Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC). Three DMF applications were submitted for lurbinectedin. Similarly, ruxolitinib phosphate, used for the treatment of patients with intermediate or high-risk myelofibrosis, also received three DMF applications.Semaglutide — the glucagon-like peptide-1 receptor agonist that catapulted Novo Nordisk to the position of the most valuable public company in Europe — received three DMF filings. Semaglutide’s arch rival, tirzepatide, also drew three DMF filings.AstraZeneca’s Brilinta (ticagrelor) plus aspirin is currently approved in over 115 countries for the prevention of stroke, heart attack, and other events in adults with acute coronary syndrome (ACS). Ticagrelor received three DMF submissions. Vonoprazan fumarate, a first-in-class potassium-competitive acid blocker to treat acid-related diseases, also received three DMF submissions.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Eighteen DMFs filed for first time in Q1 2024 During the first quarter of this year, 14 drugs saw first time filing of DMFs. Together, these 14 drugs attracted 18 DMF filings with tirzepatide topping the list with three submissions from Chinese companies.The 14 drugs that saw first time filing were clascoterone, capmatinib hydrochloride, niraparib tosylate monohydrate, vibegron, cabozantinib sulfate, ruxolitinib hemifumarate, ripretinib, ruxolitinib, ruxolitinib mesylate, tucatinib hemiethanolate, tecovirimat, tirzepatide, tolvaptan povidone, and azilsartan.View FDA DMF Filings in Q1 2024 (Power BI Dashboard, Free Excel Available) Our viewUntil 2020, DMF submissions by Indian companies used to be double those of Chinese and American firms put together. In 2022, DMF filings from India began to dip, while submissions by Chinese companies began to rise. In the first half of 2023, there was a 46.5 percent rise in DMF submissions from China. The gap between DMF filings by India and China has narrowed down considerably this year. The reasons behind this phenomenon may be multiple. But it definitely implies that America will find it increasingly difficult to reduce its reliance on China.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3301

    https://www.pharmacompass.com/radio-compass-blog/dmf-submissions-from-china-jump-42-as-india-continues-to-top-list-in-q1-2024

    #PharmaFlow by PHARMACOMPASS
    23 May 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    The August Suzhou meeting concluded successfully!
    The August Suzhou meeting concluded successfully!

    26 Aug 2024

    // PRESS RELEASE

    http://www.elixir-pharm.com/news/show/6.html

    PRESS RELEASE
    26 Aug 2024
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    ABOUT THIS PAGE

    Contact Sichuan Elixir Pharmaceuticals and get a quotation

    Sichuan Elixir Pharmaceuticals is a supplier offers 35 products (APIs, Excipients or Intermediates).

    Find a price of 7-Ethyl-10-Hydroxycamptothecin bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Cabazitaxel bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Cabozantinib bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Cytisine bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Dasatinib bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Methotrexate bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Nilotinib bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Ursodeoxycholic Acid bulk with DMF offered by Sichuan Elixir Pharmaceuticals

    Find a price of Abemaciclib bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Acalabrutinib bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Alectinib Hydrochloride bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Berberine Hydrochloride bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Bufalin bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Conjugated Estrogens bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Dabrafenib Mesylate bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Daprodustat bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Darolutamide bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Diosmin bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Enasidenib bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Etrasimod bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Exatecan bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Ferric Carboxymaltose bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Fezolinetant bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Finerenone bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Irinotecan Hydrochloride bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Larotrectinib bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Leuprolide Mesylate bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Niraparib Tosylate bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Osimertinib Mesylate bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Resmetirom bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Rutin bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Trametinib bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Troxerutin bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Venetoclax bulk offered by Sichuan Elixir Pharmaceuticals

    Find a price of Vericiguat bulk offered by Sichuan Elixir Pharmaceuticals

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search